Related Experiment Video
Updated: Jun 24, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
The use of endostatin in the treatment of solid tumors
Michalis V Karamouzis1, Stergios J Moschos
1Department of Biological Chemistry, National & Kapodistrian University of Athens Medical School, Athens, Greece.
Background:
Endostatin represents the most studied endogenous anti-angiogenesis peptide that has been found to inhibit angiogenesis and exhibit broad-spectrum antitumor activity in animal models. Clinical trials evaluating endostatin alone or in combination with other currently used strategies for the treatment of solid tumors has generated debatable efficacy results, albeit with low toxicity, immunogenicity and resistance.
Objective/Methods:
We delineate the current knowledge regarding endostatin's mechanism of action during carcinogenesis, spotlight already reported and ongoing research concerning its clinical development, and discuss future perspectives and challenges for its potential therapeutic utility.
Results/Conclusions:
After more than a decade of intense basic and clinical research since its original discovery it is still unclear whether endostatin has any clinically meaningful role in cancer therapeutics and more questions than answers have emerged.
Insights
Endostatin, an anti-angiogenesis peptide, shows antitumor potential but clinical trials yield unclear results. Further research is needed to determine its therapeutic role in cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Endostatin is a well-studied endogenous anti-angiogenesis peptide.
- It demonstrates broad-spectrum antitumor activity in preclinical animal models.
- Clinical trials show debatable efficacy for endostatin in solid tumors, despite low toxicity.
Purpose of the Study:
- To review current knowledge on endostatin's mechanism in carcinogenesis.
- To highlight ongoing clinical research and development of endostatin.
- To discuss future challenges and perspectives for endostatin's therapeutic use.
Main Methods:
- Literature review of basic and clinical research on endostatin.
- Analysis of clinical trial data regarding endostatin efficacy and safety.
- Discussion of endostatin's mechanism of action and therapeutic potential.
Main Results:
- Endostatin inhibits angiogenesis and exhibits antitumor effects in animal models.
- Clinical trials have yielded inconsistent efficacy results for endostatin.
- Low toxicity, immunogenicity, and resistance are noted with endostatin therapy.
Conclusions:
- Despite extensive research, endostatin's clinical significance in cancer therapy remains uncertain.
- More questions than answers exist regarding endostatin's role in cancer treatment.
- Further investigation is required to clarify endostatin's therapeutic utility.
